2 Information about ertugliflozin

Information about ertugliflozin

Marketing authorisation

Ertugliflozin (Steglatro, Merck Sharp & Dohme) is indicated 'in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:

  • as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications

  • in addition to other medicinal products for the treatment of diabetes'.

Dosage in the marketing authorisation

'The recommended starting dose of ertugliflozin is 5 mg once daily. In patients tolerating ertugliflozin 5 mg once daily, the dose can be increased to 15 mg once daily if additional glycaemic control is needed.'


5 mg (28 tablets) or 15 mg (28 tablets): £29.40 per pack (excluding VAT; company submission). Costs may vary in different settings because of negotiated procurement discounts.

  • National Institute for Health and Care Excellence (NICE)